
## CLAIMS

1. A compound of Formula II:



(II),

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

Y is $C_3$-$C_8$ cycloalkyl, 3- to 8-membered heterocycloalkyl, $C_5$-$C_{10}$ aryl, or 5- to 9-membered heteroaryl, wherein the $C_3$-$C_8$ cycloalkyl, 3- to 8-membered heterocycloalkyl, $C_5$-$C_{10}$ aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, 3- to 8-membered heterocycloalkyl, $C_5$-$C_{10}$ aryl, 5- to 9-membered heteroaryl, halo, cyano, $-R^4OR^5$, $-R^4N(R^5)(R^6)$, $-R^4SR^6$, $-R^4C(O)OR^6$, $-R^4C(O)N(R^7)(R^8)$, $-R^4N(R^7)C(O)R^8$, $-R^4S(O)_tR^5$, $-R^4S(O)_tN(R^7)(R^8)$, $-R^4N(R^7)S(O)_t(R^8)$, $-R^4P(O)(R^5)_2$, or $-R^4SF_5$;

$R^1$ is $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_1$-$C_6$ haloalkyl, wherein the $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, or $C_1$-$C_6$ haloalkyl is optionally substituted with one more halo, or $-R^4OR^5$,

$R^2$ and $R^3$, together with the atoms to which they are attached, form a $C_3$-$C_8$ cycloalkyl, 3- to 8-membered heterocycloalkyl, or 5- to 9-membered heteroaryl, wherein the $C_3$-$C_8$ cycloalkyl, 3- to 8-membered heterocycloalkyl, $C_5$-$C_{10}$ aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more $R^{2a}$;


$R^{2a}$ is hydrogen, $C_1$-$C_6$ alkyl, halo or $C_1$-$C_6$ haloalkyl;

$R^4$ is absent, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, or $C_2$-$C_6$ alkynyl;


$R^5$ is hydrogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, 3- to 8-membered heterocycloalkyl, $C_5$-$C_{10}$ aryl, or 5- to 9-membered heteroaryl.

2. The compound of any one of the preceding claims, wherein **$R^2$** and **$R^3$**, together with the atoms to which they are attached, form a 5- to 9-membered heteroaryl,.

3. The compound of any one of the preceding claims, wherein **$R^2$** and **$R^3$**, together with the atoms to which they are attached, form




4. The compound of any one of the preceding claims, wherein the compound of formula (II) is a compound of formula **(II-h)**:



(II-h),

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

**$R^1$** is $C_1$-$C_6$ alkyl substituted with one more halo, -$R^4OR^5$; and

**Y** is 3- to 8-membered heterocycloalkyl, $C_5$-$C_{10}$ aryl, or 5- to 9-membered heteroaryl, wherein the 3- to 8-membered heterocycloalkyl, $C_5$-$C_{10}$ aryl, or 5- to 9-membered heteroaryl is optionally substituted with one, two, or three of any of $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, halo, cyano, or -$R^4OR^5$. 5. The compound of claim 1, wherein **Y** is phenyl substituted with one or more $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, halo, cyano, or -$R^4OR^5$.

6. The compound of any one of the preceding claims, wherein **$R^1$** is 



7. The compound of any one of the preceding claims, wherein **Y** is phenyl substituted with one or more $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, halo, cyano, or -$R^4OR^5$, wherein at least one substitution is substituted at the para-position of the phenyl ring.

8. The compound of any one of the preceding claims, wherein **Y** is phenyl substituted with two $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, halo, cyano, or -$R^4OR^5$, wherein at least one substitution is substituted at the para-position of the phenyl ring.


9. The compound of any one of the preceding claims, wherein **$R^4$** is absent.

10. The compound of any one of the preceding claims, wherein **$R^5$** is hydrogen.

11. A compound of any one of the preceding claims, wherein


**Y** is phenyl substituted with one or more $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, halo, cyano, or -$R^4OR^5$;

**$R^1$** is




;

**$R^2$ and $R^3$**, together with the atoms to which they are attached, form




;


**R4** is absent, and

**R5** is hydrogen.

12. A compound of claim 4, wherein

Y is phenyl substituted with one or more $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_3$-$C_8$ cycloalkyl, halo, cyano, or -$R^4OR^5$;

**$R^1$** is





;


$\mathbf{R^{2a}}$ is hydrogen,

$\mathbf{R^{4}}$ is absent, and

$\mathbf{R^{5}}$ is hydrogen.

13. The compound of any one of the preceding claims, wherein $\mathbf{R^{1}}$ is 

.

14. The compound of any one of the preceding claims, wherein $\mathbf{R^{2}}$ and $\mathbf{R^{3}}$ , together with the atoms to which they are attached, form 

.

15. A pharmaceutical composition comprising the compound of any one of the preceding claims and one or more pharmaceutically acceptable carriers.

16. The compound or composition of any one of the preceding claims, for use in treating or preventing a disease or disorder.

17. Use of the compound or composition of any one of claims 1-15 in the manufacture of a medicament for treating or preventinga disease or disorder.

18. The compound or composition of claim 16 or use of claim 17 wherein the disease or disorder is related to NLRP3.